Catalyst Biosciences, Inc. (CBIO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2046 |
| Open | 0.2080 |
| Bid | 0.2048 x 1800 |
| Ask | 0.2077 x 1800 |
| Day's Range | 0.2000 - 0.2101 |
| 52 Week Range | 0.1900 - 2.0900 |
| Volume | |
| Avg. Volume | 1,518,217 |
| Market Cap | 7.816M |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9320 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 13, 2023 |
| 1y Target Est | 16.00 |
- Insider Monkey
12 Cheap Healthcare Stocks to Buy in 2023
In this piece, we will take a look at the twelve cheap healthcare stocks to buy in 2023. For more healthcare stocks, head on over to 5 Cheap Healthcare Stocks to Buy in 2023. The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades. Modern […]
- GlobeNewswire
Catalyst Biosciences Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”)
- GlobeNewswire
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21
